Evidence map›Paper›PMID 33792714›Full record

ArticleThe Journal of antimicrobial chemotherapy2021

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

Andrew D Revell, Dechao Wang, Maria-Jesus Perez-Elias, Robin Wood, Dolphina Cogill, Hugo Tempelman, Raph L Hamers, Peter Reiss, Ard van Sighem, Catherine A Rehm and 6 more

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrew D RevellThe HIV Resistance Response Database Initiative (RDI), London, UK.
Dechao WangThe HIV Resistance Response Database Initiative (RDI), London, UK.
Maria-Jesus Perez-EliasInstituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.ORCID 0000-0001-5700-5257
Robin WoodDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Dolphina CogillDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Hugo TempelmanNdlovu Care Group, Elandsdoorn, South Africa.
Raph L HamersDepartments of Internal Medicine and Global Health, Academic Medical Centre of the University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.ORCID 0000-0002-5007-7896
Peter ReissDepartments of Internal Medicine and Global Health, Academic Medical Centre of the University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Ard van SighemStichting HIV Monitoring, Amsterdam, The Netherlands.
Catherine A RehmNational Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Brian AganUniformed Services University of the Health Sciences and Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Gerardo Alvarez-UriaRural Development Trust (RDT) Hospital, Bathalapalli, India.
Julio S G MontanerBC Centre for Excellence in HIV/AIDS, Vancouver, Canada.
H Clifford LaneNational Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Brendan A LarderThe HIV Resistance Response Database Initiative (RDI), London, UK.
RDI study group

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Pathogenesis and Treatment of HIV InfectionZIAAI000585 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LANE, CLIFFORD · 2009 to 2025
$26.8M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

objectivesWith the goal of facilitating the use of HIV-TRePS to optimize therapy in settings with limited healthcare resources, we aimed to develop computational models to predict treatment responses accurately in the absence of commonly used baseline data.

methodsTwelve sets of random forest models were trained using very large, global datasets to predict either the probability of virological response (classifier models) or the absolute change in viral load in response to a new regimen (absolute models) following virological failure. Two 'standard' models were developed with all baseline variables present and 10 others developed without HIV genotype, time on therapy, CD4 count or any combination of the above.

resultsThe standard classifier models achieved an AUC of 0.89 in cross-validation and independent testing. Models with missing variables achieved AUC values of 0.78-0.90. The standard absolute models made predictions that correlated significantly with observed changes in viral load with a mean absolute error of 0.65 log10 copies HIV RNA/mL in cross-validation and 0.69 log10 copies HIV RNA/mL in independent testing. Models with missing variables achieved values of 0.65-0.75 log10 copies HIV RNA/mL. All models identified alternative regimens that were predicted to be effective for the vast majority of cases where the new regimen prescribed in the clinic failed. All models were significantly better predictors of treatment response than genotyping with rules-based interpretation.

conclusionsThese latest models that predict treatment responses accurately, even when a number of baseline variables are not available, are a major advance with greatly enhanced potential benefit, particularly in resource-limited settings. The only obstacle to realizing this potential is the willingness of healthcare professions to use the system.

Indexed as

Anti-HIV AgentsHIV InfectionsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountDelivery of Health CareGenotypeHIVHumansRNA, ViralViral LoadAnti-HIV AgentsRNA, Viral

Identifiers

PMID33792714
PMCPMC8212763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.